Bemrist Breezhaler


indacaterol / mometasone

This medicine is authorised for use in the European Union.


Bemrist Breezhaler is a medicine that is used to keep the airways open in adults and children aged 12 years and older whose asthma is not adequately controlled with inhaled corticosteroids and inhaled short acting beta-2 agonists. Bemrist Breezhaler is used for maintenance (regular) treatment. 

The medicine contains the active substances indacaterol and mometasone.

This EPAR was last updated on 24/06/2020

Authorisation details

Product details
Bemrist Breezhaler
Agency product number
Active substance
  • indacaterol
  • Mometasone furoate
International non-proprietary name (INN) or common name
  • indacaterol
  • mometasone
Therapeutic area (MeSH)
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Novartis Europharm Limited 
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Vista Building
Elm Park
Merrion Road
Dublin 4

Product information

30/05/2020 Bemrist Breezhaler - EMEA/H/C/005516 -


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs for obstructive airway diseases

Therapeutic indication

Bemrist Breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Assessment history

How useful was this page?

Add your rating